Church & Dwight
CHD
$98.42
+0.10%
Church & Dwight Co., Inc. is a leading consumer packaged goods company operating in the Household & Personal Products industry, best known as the global leader in baking soda production and the owner of the iconic Arm & Hammer brand. The company has successfully diversified its portfolio beyond its legacy product into a multi-brand platform encompassing laundry care (OxiClean), cat litter, oral care, deodorant, nasal care, and vitamins (Vitafusion), with its core brands accounting for approximately 70% of sales and profits. The current investor narrative centers on the company's ability to navigate a challenging consumer environment, with recent attention focused on its Q4 2025 earnings report, which showed modest revenue growth but a significant year-over-year decline in net income, raising questions about margin pressures and the integration and performance of recent acquisitions like Touchland.…
CHD
Church & Dwight
$98.42
Investment Opinion: Should I buy CHD Today?
Recommendation: Hold. CHD is a fundamentally sound company navigating a period of profitability pressure, making it unsuitable for new investment until evidence of a margin turnaround emerges.
Thesis: While CHD possesses strong brands and cash generation, its premium valuation is unjustified given the clear deterioration in profitability metrics and lack of positive price momentum. The stock's defensive, low-beta nature provides downside protection but also limits upside potential in the current environment. Analyst sentiment, as indicated by recent upgrades from Rothschild & Co and JP Morgan to Neutral, reflects this cautious, wait-and-see stance. Supporting this view are four key data points: 1) a high trailing P/E of 27.6x, 2) a 24.2% YoY decline in Q4 net income, 3) a -24.39 relative strength score indicating severe underperformance, and 4) a forward P/E of 23.9x that still prices in a recovery not yet evident in the results.
This Hold rating would upgrade to a Buy if the forward P/E compresses below 20x (offering a larger margin of safety) or if quarterly gross margins demonstrate a sustained recovery above 47%. Conversely, it would downgrade to a Sell if revenue growth decelerates below 2% or if the stock breaks below its 52-week low of $81.33, confirming the bearish trend. Relative to its own historical P/E range and sector peers, CHD is currently overvalued, as the market price implies an earnings recovery that the recent financials have not yet delivered.
Sign up to view all
CHD 12-Month Price Forecast
The outlook for CHD is one of muted expectations. The company's strong fundamentals are currently overshadowed by acute margin pressures, creating a stalemate between value and momentum. The base case (60% probability) of range-bound trading is most likely, as the stock's defensive attributes prevent a crash while its earnings challenges cap rallies. The stance is neutral with medium confidence; the path forward is highly dependent on the next 1-2 quarterly earnings reports. An upgrade to bullish would require concrete evidence of margin stabilization and a breakout above $106. A downgrade to bearish would be triggered by a breakdown below $81.33, signaling the bear case is materializing.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Church & Dwight's 12-month outlook, with a consensus price target around $127.95 and implied upside of +30.0% versus the current price.
Average Target
$127.95
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$79 - $128
Analyst target range
Analyst coverage for CHD appears limited in the provided dataset, with only one analyst providing estimates for revenue and EPS, which is insufficient to derive a meaningful consensus target price or recommendation distribution. The single analyst estimates for the next period include an average EPS of $4.78 and average revenue of $7.22 billion. The lack of a broad consensus and the minimal number of analysts suggest this may be a coverage gap in the provided data, as a company of CHD's market cap ($20.35 billion) typically garners more attention. Without a consensus target, it is difficult to gauge institutional sentiment, though recent rating actions from firms like Rothschild & Co (upgraded from Sell to Neutral in February 2026) and JP Morgan (upgraded from Underweight to Neutral) indicate a slight, cautious improvement in sentiment, moving from bearish to neutral stances.
Bulls vs Bears: CHD Investment Factors
The investment debate for CHD centers on a clash between its strong defensive characteristics and deteriorating profitability. The bull case is anchored by robust free cash flow ($1.093B TTM), a low-beta defensive profile, and a powerful brand portfolio. However, the bear case presents compelling evidence with severe margin compression (net income down 24.2% YoY) and a premium valuation (27.6x P/E) that appears unsustainable without a swift earnings recovery. Currently, the bearish evidence holds more weight due to the concrete, negative earnings trajectory. The single most important tension is whether the Q4 2025 margin collapse is a temporary blip related to integration costs and inflation, or the beginning of a sustained erosion of the company's pricing power and profitability in a competitive CPG landscape.
Bullish
- Strong Free Cash Flow Generation: The company generates substantial cash, with trailing twelve-month free cash flow of $1.093 billion. This robust cash flow provides significant financial flexibility for dividends, share buybacks, and strategic acquisitions, supporting a defensive profile.
- Defensive Business with Low Beta: CHD's beta of 0.47 indicates it is significantly less volatile than the broader market, a characteristic of a stable consumer staples company. This makes it a potential safe haven during market downturns, as evidenced by its -24.39 relative strength underperformance during the S&P 500's 22.86% rally.
- Healthy Balance Sheet & ROE: A conservative debt-to-equity ratio of 0.55 and a strong return on equity of 18.41% demonstrate a solid financial foundation and efficient capital allocation. This provides a margin of safety and capacity for strategic investments.
- Leading Brand Portfolio: Approximately 70% of sales and profits come from its core, market-leading brands like Arm & Hammer and OxiClean. This portfolio strength, particularly in essential categories, provides pricing power and resilience in a challenging consumer environment.
Bearish
- Significant Profit Margin Compression: Q4 2025 net income fell 24.2% year-over-year to $143.5M, and the quarterly net margin compressed to 8.73% from 11.98% in Q4 2024. This severe profitability decline, coupled with a gross margin drop from 47.15% in Q2 2024 to 45.85% in Q4 2025, raises concerns about cost inflation and competitive pressures.
- Premium Valuation Amidst Weak Performance: A trailing P/E of 27.62x is high for the defensive Consumer Defensive sector. This premium valuation is difficult to justify given the stock's 1-year price decline of 1.53% and significant underperformance versus the S&P 500.
- Decelerating Revenue Growth: While Q4 2025 revenue grew 3.93% YoY to $1.644B, this represents a deceleration from stronger prior quarters. The modest growth, in the context of recent acquisitions like Touchland, suggests underlying organic growth may be challenged.
- Technical Downtrend & Underperformance: The stock is in a clear downtrend from its 52-week high of $106.04, with a -24.39 relative strength reading versus the S&P 500 over the past year. This persistent underperformance indicates waning investor confidence and a lack of positive momentum catalysts.
CHD Technical Analysis
The stock is in a clear downtrend from its 52-week highs, having declined 1.53% over the past year, significantly underperforming the S&P 500, which gained 22.86% over the same period, as evidenced by a stark -24.39 relative strength reading. Currently trading at $97.56, the price sits roughly in the middle of its 52-week range of $81.33 to $106.04, indicating a lack of decisive directional momentum and positioning the stock in a neutral zone between support and resistance. The 1-month return of +2.60% offers a glimmer of positive short-term momentum, but this is contrasted by a slightly negative 3-month return of -0.19%, suggesting the recent uptick is fragile and has not yet reversed the longer-term bearish trend established by the 1-year performance. Key technical support is clearly defined at the 52-week low of $81.33, while immediate overhead resistance is at the 52-week high of $106.04; a sustained break above $106 would signal a potential trend reversal, while a breakdown below $81.33 would confirm a continuation of the downtrend. With a beta of 0.47, CHD exhibits significantly lower volatility than the broader market, behaving as a defensive stock, which is consistent with its consumer staples profile but also implies limited participation in broader market rallies.
Beta
0.47
0.47x market volatility
Max Drawdown
-18.1%
Largest decline past year
52-Week Range
$81-$106
Price range past year
Annual Return
+0.6%
Cumulative gain past year
| Period | CHD Return | S&P 500 |
|---|---|---|
| 1m | +4.6% | +1.5% |
| 3m | +2.8% | +13.4% |
| 6m | +15.7% | +10.9% |
| 1y | +0.6% | +24.5% |
| ytd | +19.1% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CHD Fundamental Analysis
Revenue growth has been modest but positive, with Q4 2025 revenue of $1.644 billion representing a 3.93% year-over-year increase; however, this growth rate appears to be decelerating from the stronger performance seen in prior quarters, such as Q2 2025 where revenue was $1.506 billion. The company remains profitable, but profitability metrics show concerning pressure, as Q4 2025 net income of $143.5 million declined substantially from $189.2 million in the year-ago quarter, and the quarterly gross margin of 45.85% is down from the 47.15% reported in Q2 2024. The trailing twelve-month free cash flow is a robust $1.093 billion, indicating strong cash generation, but the quarterly net income margin of 8.73% in Q4 2025 is compressed compared to the 11.98% net margin from Q4 2024. The balance sheet is conservatively managed with a debt-to-equity ratio of 0.55, and the current ratio of 1.07 suggests adequate, though not ample, short-term liquidity; the return on equity of 18.41% remains healthy, demonstrating efficient use of shareholder capital despite the recent earnings pressure.
Quarterly Revenue
$1.6B
2025-12
Revenue YoY Growth
+0.03%
YoY Comparison
Gross Margin
+0.45%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CHD Overvalued?
Given the company's consistent profitability with a positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio stands at 27.62x, while the forward P/E is 23.86x, indicating the market anticipates earnings growth, as the forward multiple is a 13.6% discount to the trailing figure. Compared to the Consumer Defensive sector, which typically trades at lower multiples, CHD's trailing P/E of 27.6x represents a significant premium, justified only if the company can demonstrate a return to stronger earnings growth and defend its market-leading brand positions. Historically, the stock's own P/E has fluctuated, with recent quarterly data showing a range from approximately 23x to over 37x; the current trailing P/E of 27.6x sits above the middle of this historical band, suggesting the stock is not cheap relative to its own history and that the market has already priced in a recovery from the Q4 earnings dip.
PE
27.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -85x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary risk is sustained margin compression, as evidenced by the Q4 2025 net income decline of 24.2% year-over-year and a quarterly net margin contraction from 11.98% to 8.73%. While free cash flow remains strong at $1.093 billion TTM, this profitability pressure threatens the company's ability to fund growth initiatives and shareholder returns if it persists. Furthermore, the company's success is concentrated in its core brands, which drive ~70% of sales, creating vulnerability if any major brand loses market share. The recent acquisition of Touchland also introduces integration and execution risk, potentially diverting management focus and capital.
Market & Competitive Risks: CHD trades at a significant premium valuation with a trailing P/E of 27.6x, which is high for the typically lower-multiple Consumer Defensive sector. This creates valuation compression risk if earnings growth fails to materialize, as the stock could de-rate towards sector averages. The stock's low beta of 0.47, while defensive, also implies it may not participate fully in market rallies, as seen in its -24.39 relative underperformance over the past year. Competitive pressures from both large rivals and private-label brands could force increased marketing spend or price reductions, further pressuring the already declining gross margins.
Worst-Case Scenario: The worst-case scenario involves a failure to stabilize margins, leading to consecutive earnings misses and downward revisions. This could trigger multiple compression as the premium valuation unwinds, combined with sector rotation out of defensive names if the broader market rallies. A breakdown below key technical support at the 52-week low of $81.33 would likely accelerate selling. In this adverse scenario, a realistic downside from the current price of $97.56 is approximately -16.7% to the 52-week low, with potential for further declines if sentiment sours drastically, approaching the stock's historical max drawdown of -18.1%.
FAQ
The key risks are, in order of severity: 1) Profit Margin Erosion: The most immediate risk is the continuation of the Q4 trend, where net income fell 24.2% and margins compressed significantly. 2) Valuation Compression: The high P/E of 27.6x could contract sharply if earnings disappoint, leading to a double-whammy of lower earnings and a lower multiple. 3) Competitive & Integration Pressures: The company must defend its core brands (~70% of sales) while successfully integrating acquisitions like Touchland in a tough consumer environment. 4) Market Underperformance: With a beta of 0.47, the stock may continue to lag in a rising market, as evidenced by its -24.39 relative strength over the past year.
The 12-month forecast presents three scenarios. The Base Case (60% probability), target range $90-$105, expects the stock to remain range-bound with modest growth and gradual margin improvement. The Bull Case (25% probability), target $106-$115, requires a successful earnings turnaround leading to a breakout. The Bear Case (15% probability), target $81-$85, involves continued margin pressure and a re-test of the 52-week low. The base case is most likely, centered on the stock trading between its clear technical support and resistance levels while the company works through its profitability challenges. The key assumption is that margin deterioration halts but a robust recovery remains elusive.
CHD appears overvalued based on current fundamentals. Its trailing P/E of 27.6x is at a premium to the typical Consumer Defensive sector, yet the company is experiencing severe profit margin compression. Historically, its own P/E has ranged from ~23x to over 37x; the current multiple sits above the midpoint of this range despite weaker earnings. The forward P/E of 23.9x suggests the market is pricing in an earnings recovery that has not yet materialized. Therefore, the valuation implies optimistic growth expectations that recent financials do not support, making the stock look expensive.
CHD is not a compelling buy at current levels for most investors. While the company has strong brands and cash flow, the stock is overvalued (27.6x trailing P/E) relative to its recent profit decline (-24.2% YoY net income in Q4). The significant underperformance versus the market (-24.39 relative strength) and lack of positive momentum further dampen the near-term outlook. It could be a good buy for very patient, defensive-oriented investors only if the price drops significantly to provide a larger margin of safety, perhaps near its 52-week low of $81.33, or after clear evidence of a margin recovery emerges.
CHD is primarily suitable for a long-term investment horizon of 3-5 years. Its low beta (0.47) and defensive business model make it a poor candidate for short-term trading, as it lacks the volatility and momentum typically sought. For long-term holders, the strong brand portfolio and consistent free cash flow generation ($1.093B TTM) can compound value, but investors must be willing to endure potential near-term volatility and uncertainty regarding the margin recovery. The stock pays a modest dividend (yield ~1.4%), adding to its appeal for income-oriented, long-term portfolios. A minimum holding period of 2-3 years is suggested to allow the company's operational initiatives to play out.